VYLOY Patent Extension Comment Period Notice

Detected April 3rd, 2026

Summary

The FDA has opened a 60-day public comment period for a patent extension application related to the drug VYLOY (zolbetuximab). Pharmaceutical companies and other interested parties may submit comments on the patent term restoration matter. The comment period provides an opportunity for stakeholders to voice concerns or support regarding the extension.

View original document View source feed page

What changed

The FDA published a notice on Regulations.gov (Docket FDA-2025-E-0865-0006) initiating a 60-day public comment period for a patent extension application concerning VYLOY, a targeted oncology therapy. Patent extensions under the Hatch-Waxman Act allow for restoration of patent term lost during the FDA regulatory review process. The notice invites public comments on whether the extension should be granted.

Pharmaceutical companies and patent holders with interests in VYLOY or similar biologics should monitor this proceeding and submit relevant comments if applicable. The 60-day comment window is standard for patent-related FDA notices. No specific compliance deadlines or penalties are associated with this consultation itself.

What to do next

Monitor Federal Register and Regulations.gov for updates on FDA-2025-E-0865-0006
Prepare and submit public comments if your organization has standing or interest in the VYLOY patent extension
Review patent term restoration requirements under 21 CFR Part 60 for similar applications

Source document (simplified)

Write a Comment

Commenter's Checklist
Public Comments on Federal Regulations

Comment *

5000

What is your comment about?

Attach Files

You can attach up to 20 files, but each file cannot exceed 10MB. Valid file types include: bmp, docx, gif, jpg, jpeg, pdf, png, pptx, rtf, sgml, tif, tiff, txt, wpd, xlsx, xml. Drop files here or Browse...

Email Address

Opt to receive email confirmation of submission and tracking number?
If you choose to identify as Anonymous, the option to receive an email confirmation will not be displayed. (We will never post the email address entered in the field above on Regulations.gov nor share it with anyone else.)

Tell us about yourself! I am... *

(Select an identity below)

An Individual

Yourself or another person whom
you represent with their consent

An Organization

A company, organization,
or government agency

Anonymous

A person who does not want their name
associated with the comment

Note: If you choose to identify as Anonymous, the option to enter your email address for submission confirmation is not available.

reCAPTCHA *

Solve with 2Captcha Do not submit personally identifiable information through this form. Any personally identifiable information (e.g., name, address, phone number) included in the comment form or in an attachment may be publicly disclosed in a docket or on the Internet (via Regulations.gov, a federal agency website, or a third-party, non-government website with access to publicly-disclosed data on Regulations.gov). By submitting a comment, you agree to the terms of participation and privacy notice.

Submit Comment

Please see the Privacy Notice and User Notice regarding comment submission.

Any information (e.g., personal or contact) you provide on this comment form or in an attachment may be publicly disclosed and searchable on the Internet and in a paper docket and will be provided to the Department or Agency issuing the notice. To view any additional information for submitting comments, such as anonymous or sensitive submissions, refer to the Privacy Notice and User Notice, the Federal Register notice on which you are commenting, and the Web site of the Department or Agency.